São Paulo, Brazil, 26 June 2025 — MicroPort® Endovastec™ is proud to announce the first successful clinical implantation of its Talos™ Thoracic Stent Graft System (Talos™) in South America. The procedure was performed by Prof. Bruna de Fina, Dr. Henrique Elkis, Dr. Guilherme Centofanti, and their team from Samaritano Paulista Hospital in São Paulo, Brazil.
The patient, an 81-year-old male, diagnosed with Stanford type B aortic dissection, was evaluated using CTA imaging, which showed a substantial extent of the dissection. Prof. Bruna de Fina chose Talos™ to isolate the distal aortic rupture and innovatively combined it with the Castor™ Branched Stent Graft to reconstruct the patient's aortic arch. Castor™’s unique unibody design expands the proximal anchoring zone, while Talos™’s long coverage (up to 260mm) and unique distal honeycomb design effectively remodel the distal true lumen. This approach sealed the proximal rupture and maintained continuous perfusion to the intercostal arteries, thereby reducing the risk of spinal ischemia and paralysis.
Talos™ is a next-generation straight thoracic stent graft system, and the world’s first “breathing” stent graft specifically designed for the treatment of Stanford type B aortic dissection. By extending stent length, it enhances remodeling of the distal true lumen. Its unique distal honeycomb design enlarges the distal true lumen diameter of the thoracic aorta and reduces the risk of spinal cord ischemia related to overlying intercostal arteries, improving long-term outcomes. With a maximum stent length of 260 mm, Talos™ is designed to optimize aortic remodeling outcomes in complex cases.
Talos™ has been approved for clinical use in multiple countries, including China, Argentina and Ecuador, and is currently used across more than 400 hospitals. The successful implantation in Brazil represents a key step forward in its continued global expansion.
About MicroPort® Endovastec™
Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
More information is available at: www.endovastec.com/en